{"entity":{"id":"mark-robson","kind":"person","name":"Mark E. Robson","aka":[],"tldr":"New York breast oncologist and cancer geneticist who led OlympiAD, the trial that made olaparib the first PARP inhibitor approved for BRCA-mutated breast cancer.","summary":"Mark Robson leads the breast medicine service at Memorial Sloan Kettering Cancer Center and works at the interface of clinical genetics and breast oncology. He was first author of the 2017 New England Journal of Medicine report of OlympiAD, which showed that olaparib improved progression-free survival compared with standard chemotherapy in HER2-negative metastatic breast cancer with a germline BRCA mutation, the first PARP inhibitor approval in breast cancer.","asOf":"2026-09-18","links":[],"tags":["breast","genetics","trialist"],"related":[],"cancers":["tnbc-metastatic","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-olympiad-nejm-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of the Breast Medicine Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Hereditary breast cancer","PARP inhibitors","Clinical cancer genetics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robson%5BAuthor%5D"}],"papers":[{"title":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1706450","doi":"10.1056/NEJMoa1706450"}],"orcid":"0000-0002-3109-1692"},"route":"/people/mark-robson/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"paper":[{"id":"paper-asco-hereditary-breast-cancer-guideline-jco-2020","kind":"paper","name":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","route":"/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/"},{"id":"paper-olympiad-nejm-2017","kind":"paper","name":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","route":"/key-papers/paper-olympiad-nejm-2017/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}